What is Bio-Techne?
Bio-Techne is a life sciences reagents and instruments company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Life sciences reagents and instruments
- Headquarters
- Minneapolis, MN
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: TECH
What is Bio-Techne?
Bio-Techne is a life sciences reagents and instruments company headquartered in Minneapolis, MN. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Bio-Techne is a life sciences reagents and instruments company headquartered in Minneapolis, MN. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Bio-Techne should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Bio-Techne offer?
Bio-Techne's profile centers on Reagents, Proteins, Antibodies, Diagnostics.
- Reagents· Life sciences reagents and instruments
- Proteins· Life sciences reagents and instruments
- Antibodies· Life sciences reagents and instruments
- Diagnostics· Life sciences reagents and instruments
- Spatial biology· Life sciences reagents and instruments
- Analytical instruments· Life sciences reagents and instruments
How does Bio-Techne make money?
Bio-Techne makes money through commercial activity tied to life sciences reagents and instruments.
Bio-Techne monetizes through the model common to life sciences reagents and instruments: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Bio-Techne?
Bio-Techne's named executives should be verified on the official leadership or investor-relations page before outreach.
- Bio-Techne executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Bio-Techne finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Bio-Techne operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Bio-Techne's leadership?
Bio-Techne should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.bio-techne.com- Bio-Techne investor relationsInvestor relations / corporate contactcontact via https://www.bio-techne.com
- Bio-Techne media relationsMedia or communications contact routecontact via https://www.bio-techne.com
How is Bio-Techne funded?
Bio-Techne's current status is Public company; Nasdaq: TECH.
Bio-Techne's capital profile is best understood through its current public-company status: Public company; Nasdaq: TECH. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Bio-Techne get here?
Bio-Techne's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingBio-Techne is foundedThe company begins building in life sciences reagents and instruments.
- Scale-upCommercial footprint expandsBio-Techne broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: TECHPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Bio-Techne's competitors?
Bio-Techne competes with larger incumbents and focused specialists in life sciences reagents and instruments.
Bio-Techne — frequently asked questions
